Enfermedad Inflamatoria Intestinal al Día最新文献

筛选
英文 中文
Adalimumab para el tratamiento de hidradenitis supurativa moderada a severa: estudio paralelo aleatorizado 阿达木单抗治疗中度至重度化脓性汗腺炎:随机平行研究
Enfermedad Inflamatoria Intestinal al Día Pub Date : 2016-01-01 DOI: 10.1016/j.eii.2015.10.001
J.R. Márquez Velásquez
{"title":"Adalimumab para el tratamiento de hidradenitis supurativa moderada a severa: estudio paralelo aleatorizado","authors":"J.R. Márquez Velásquez","doi":"10.1016/j.eii.2015.10.001","DOIUrl":"10.1016/j.eii.2015.10.001","url":null,"abstract":"","PeriodicalId":100473,"journal":{"name":"Enfermedad Inflamatoria Intestinal al Día","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.eii.2015.10.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79537060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comentarios a artículos sobre la enfermedad de Crohn 对克罗恩病文章的评论
Enfermedad Inflamatoria Intestinal al Día Pub Date : 2016-01-01 DOI: 10.1016/j.eii.2016.01.001
J.M. Benítez-Cantero, V. García-Sánchez
{"title":"Comentarios a artículos sobre la enfermedad de Crohn","authors":"J.M. Benítez-Cantero, V. García-Sánchez","doi":"10.1016/j.eii.2016.01.001","DOIUrl":"10.1016/j.eii.2016.01.001","url":null,"abstract":"","PeriodicalId":100473,"journal":{"name":"Enfermedad Inflamatoria Intestinal al Día","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.eii.2016.01.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83149896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Un nuevo enfoque de la nutrición y nutrigenómica en el tratamiento de las enfermedades inflamatorias intestinales crónicas y en la prevención de malignización 营养和营养基因组学治疗慢性炎症性肠病和预防恶性肿瘤的新方法
Enfermedad Inflamatoria Intestinal al Día Pub Date : 2016-01-01 DOI: 10.1016/j.eii.2015.11.001
A.S. Peña
{"title":"Un nuevo enfoque de la nutrición y nutrigenómica en el tratamiento de las enfermedades inflamatorias intestinales crónicas y en la prevención de malignización","authors":"A.S. Peña","doi":"10.1016/j.eii.2015.11.001","DOIUrl":"10.1016/j.eii.2015.11.001","url":null,"abstract":"","PeriodicalId":100473,"journal":{"name":"Enfermedad Inflamatoria Intestinal al Día","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.eii.2015.11.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74137959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dipropionato de beclometasona oral de liberación modificada y prednisona para el tratamiento de la colitis ulcerosa activa: resultados de un estudio doble ciego, aleatorizado y de grupos paralelos 双丙酸缓释倍氯米松口服强的松治疗活动性溃疡性结肠炎:双盲、随机、平行组研究结果
Enfermedad Inflamatoria Intestinal al Día Pub Date : 2016-01-01 DOI: 10.1016/j.eii.2016.02.001
I. Rodríguez-Lago, J.L. Cabriada
{"title":"Dipropionato de beclometasona oral de liberación modificada y prednisona para el tratamiento de la colitis ulcerosa activa: resultados de un estudio doble ciego, aleatorizado y de grupos paralelos","authors":"I. Rodríguez-Lago, J.L. Cabriada","doi":"10.1016/j.eii.2016.02.001","DOIUrl":"10.1016/j.eii.2016.02.001","url":null,"abstract":"","PeriodicalId":100473,"journal":{"name":"Enfermedad Inflamatoria Intestinal al Día","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.eii.2016.02.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83601535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ileocolitis de Crohn refractaria secundaria a colitis amebiana: un caso clínico 阿米巴结肠炎继发的难治性克罗恩回肠结肠炎:一个临床病例
Enfermedad Inflamatoria Intestinal al Día Pub Date : 2016-01-01 DOI: 10.1016/j.eii.2016.01.002
M.D. Martín Arranz , L. Guerra Pastrian
{"title":"Ileocolitis de Crohn refractaria secundaria a colitis amebiana: un caso clínico","authors":"M.D. Martín Arranz ,&nbsp;L. Guerra Pastrian","doi":"10.1016/j.eii.2016.01.002","DOIUrl":"10.1016/j.eii.2016.01.002","url":null,"abstract":"<div><p>Up to 30% of patients with Crohn's disease are refractory to corticoesteroids. Currently, these patients are treated with inmunosupressive or biologic therapies or surgery. A proper differential diagnosis must be established knowing that many infections can mimic inflamatory bowel disease, and the diagnosis is not always easy. A case of an ileocolonic Crohn's disease refractory to corticosteroid because an Entamoeba histolytica infection in a patient without epidemiologic risk factors is presented.</p></div>","PeriodicalId":100473,"journal":{"name":"Enfermedad Inflamatoria Intestinal al Día","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.eii.2016.01.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88232605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comentarios a artículos sobre colitis ulcerosa grave 对严重溃疡性结肠炎文章的评论
Enfermedad Inflamatoria Intestinal al Día Pub Date : 2016-01-01 DOI: 10.1016/j.eii.2016.02.002
I. Vera Mendoza
{"title":"Comentarios a artículos sobre colitis ulcerosa grave","authors":"I. Vera Mendoza","doi":"10.1016/j.eii.2016.02.002","DOIUrl":"10.1016/j.eii.2016.02.002","url":null,"abstract":"","PeriodicalId":100473,"journal":{"name":"Enfermedad Inflamatoria Intestinal al Día","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.eii.2016.02.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86709078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Estudio comparativo de 2 formulaciones de hierro intravenoso en una Unidad de Hospital de Día 医院日间单位两种静脉注射铁制剂的比较研究
Enfermedad Inflamatoria Intestinal al Día Pub Date : 2016-01-01 DOI: 10.1016/j.eii.2016.02.003
N. Cano , L. Oltra , J. Hinojosa
{"title":"Estudio comparativo de 2 formulaciones de hierro intravenoso en una Unidad de Hospital de Día","authors":"N. Cano ,&nbsp;L. Oltra ,&nbsp;J. Hinojosa","doi":"10.1016/j.eii.2016.02.003","DOIUrl":"10.1016/j.eii.2016.02.003","url":null,"abstract":"<div><h3>Objectives</h3><p>To compare effectiveness, efficiency and safety of two parenteral iron formulations in patients with inflammatory bowel disease: ferric-carboximaltose vs ferric-sacarose.</p></div><div><h3>Methods</h3><p>Retrospective analysis of 72 patients undergoing intravenous iron treatment. Indications of treatment: hemoglobin<!--> <!-->&lt;<!--> <!-->10<!--> <!-->g/dL and or ferritininemia<!--> <!-->&lt;<!--> <!-->100<!--> <!-->μg/L. The need of transfusion of red blood cells pools was registered, meaning the immediate closure of the follow-up of the patient. Iron protocol administration: ferric-carboximaltose (40 patients): maximum dose 1000<!--> <!-->mg in 15<!--> <!-->minutes perfusion; ferric-sacarose (32 patients): maximum dose 200<!--> <!-->mg in 1 hour perfusion.</p></div><div><h3>Results</h3><p>There were no significant differences in average levels of haemoglobin (Ferric-carboxymaltose 10.78<!--> <!-->±<!--> <!-->2.06<!--> <!-->mg/dL vs. Ferric-sucrose 10.14<!--> <!-->±<!--> <!-->2.33<!--> <!-->mg/dL), haematocrit (ferric-carboxymaltose 32.15<!--> <!-->±<!--> <!-->3.24% vs. ferric-sucrose 30.47<!--> <!-->±<!--> <!-->4.53%), MCV (ferric-carboxymaltose 72.40<!--> <!-->±<!--> <!-->7.72 fL vs. ferric-sucrose 69.54<!--> <!-->±<!--> <!-->8.46 fL) and MCH (ferric-carboxymaltose 25.43<!--> <!-->±<!--> <!-->6.22 pg/dL vs. ferric-sucrose 23.75<!--> <!-->±<!--> <!-->5.93 pg/dL). Average ferritin levels were higher in ferric-carboxymaltose group (246.74<!--> <!-->±<!--> <!-->17.83<!--> <!-->μg/L vs. 179.52<!--> <!-->±<!--> <!-->21.36<!--> <!-->μg/L; <em>P</em>=.023).</p><p>Adverse events registered in the administration of ferric-carboxymaltose were lower (2 urticarial reactions) vs. al ferric-sucrose (13 stomachache and headache cases); p<!--> <!-->&lt;<!--> <!-->0.001. 2 patients with ferric-carboxymaltose required blood transfusion vs. 6 patients with Ferric-sucrose group; p<!--> <!-->=<!--> <!-->0.062. The number of administered dosages was significantly higher in ferric-sucrose group in a ratio ferric-sucrose/ferric-carboxymaltose of 3.39 dosages/patient. Ferric-carboxymaltose application reduced treatment cost in €948.46/patient.</p></div><div><h3>Conclusions</h3><p>Treatment with intravenous ferric-carboxymaltose shows an effectiveness profile not inferior to ferric-sucrose. Higher repletion of systemic stock and a better security profile. Related to posology, treatment shows to improve efficiency, reducing dosages, blood transfusion and cost per patient.</p></div>","PeriodicalId":100473,"journal":{"name":"Enfermedad Inflamatoria Intestinal al Día","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.eii.2016.02.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82695143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Inmunogenicidad cruzada: anticuerpos para infliximab en pacientes con enfermedad inflamatoria intestinal tratados con Remicade reconocen similarmente al biosimilar Remsima 交叉免疫原性:在使用Remicade治疗的炎症性肠病患者中,英夫利昔单抗抗体识别的生物类似物Remsima相似
Enfermedad Inflamatoria Intestinal al Día Pub Date : 2016-01-01 DOI: 10.1016/j.eii.2015.12.002
J.R. Márquez Velásquez
{"title":"Inmunogenicidad cruzada: anticuerpos para infliximab en pacientes con enfermedad inflamatoria intestinal tratados con Remicade reconocen similarmente al biosimilar Remsima","authors":"J.R. Márquez Velásquez","doi":"10.1016/j.eii.2015.12.002","DOIUrl":"10.1016/j.eii.2015.12.002","url":null,"abstract":"","PeriodicalId":100473,"journal":{"name":"Enfermedad Inflamatoria Intestinal al Día","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.eii.2015.12.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83818600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Fiebre persistente en paciente con enfermedad de Crohn: enfermedad de Still del adulto 克罗恩病患者持续发热:成人斯蒂尔氏病
Enfermedad Inflamatoria Intestinal al Día Pub Date : 2015-09-01 DOI: 10.1016/j.eii.2015.09.002
L. Carrión-Martín , G. Pérez-Rial , A.I. Hernando-Alonso , L. Menchén-Viso , J. Pajares-Díaz , F.J. López-Longo , M. Valerio , M.J. Penalva-Moreno , I. Marín-Jimenez
{"title":"Fiebre persistente en paciente con enfermedad de Crohn: enfermedad de Still del adulto","authors":"L. Carrión-Martín ,&nbsp;G. Pérez-Rial ,&nbsp;A.I. Hernando-Alonso ,&nbsp;L. Menchén-Viso ,&nbsp;J. Pajares-Díaz ,&nbsp;F.J. López-Longo ,&nbsp;M. Valerio ,&nbsp;M.J. Penalva-Moreno ,&nbsp;I. Marín-Jimenez","doi":"10.1016/j.eii.2015.09.002","DOIUrl":"10.1016/j.eii.2015.09.002","url":null,"abstract":"<div><p>Extra-intestinal manifestations are frequent in Crohn's disease (CD). Adult onset Still's disease is a rare disease presenting with arthritis and arthralgia, high (<!--> <!-->&gt;<!--> <!-->39<!--> <!-->°C) and persistent fever, rash, sore throat, lymphadenopathies and hepatosplenomegaly. There are only 3 cases in literature of adult onset Still's disease presenting in CD patients. We describe a new case of adult onset Still's disease associated to connective tissue disease. Although infrequent, it is important to become aware of this disease for the differential diagnosis of arthralgia and high fever in CD patients.</p></div>","PeriodicalId":100473,"journal":{"name":"Enfermedad Inflamatoria Intestinal al Día","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2015-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.eii.2015.09.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90874609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Colitis microscópica y exposición a fármacos: una revisión crítica 显微结肠炎与药物暴露:综述
Enfermedad Inflamatoria Intestinal al Día Pub Date : 2015-09-01 DOI: 10.1016/j.eii.2015.08.004
A.J. Lucendo , F. Fernández-Bañares
{"title":"Colitis microscópica y exposición a fármacos: una revisión crítica","authors":"A.J. Lucendo ,&nbsp;F. Fernández-Bañares","doi":"10.1016/j.eii.2015.08.004","DOIUrl":"10.1016/j.eii.2015.08.004","url":null,"abstract":"<div><p>Microscopic colitis (MC) comprises 2 fundamental entities (lymphocytic colitis and collagenous colitis) defined by chronic or recurrent watery diarrhea, normal colonoscopy and characteristic histopathological features. The exposure of the colonic mucosa at different luminal antigens, including different drugs, has been involved in the still poor understood pathophysiology of MC. Thus, the relationship between the development of MC after drug exposure has been the subject of research for more than 2 decades, mainly based on observational studies, including case reports and case series, case-control studies, and data on drug prescriptions. Among others, proton-pump inhibitors, nonsteroidal antiinflammatory drugs, selective inhibitors of serotonin reuptake, beta-blockers and statins, have been linked to the onset of MC, but all these drugs are also recognized as a frequent cause of drug-associated diarrhea.</p><p>At present we have no universally accepted criteria for establishing cause-effect relationships in adverse drug reactions, although several methods have provide us with different levels of likelihood. Thus, the existence of a high probability of MC occurrence as an adverse effect to a specific drug has been shown only in individual cases by using chronological (exposure, effect of withdrawal and relapse with re-exposure) and semiological criteria. Although case-control studies have repeatedly shown significant associations between drug exposure and MC, variability in their designs, including reference populations used and the criteria considered in defining drug exposure, requires a detailed analysis. This article critically examines the complex relationship between drugs, diarrhea and MC, to conclude that a likely cause-effect relationship has only been described for few drugs and in individual cases of MC.</p></div>","PeriodicalId":100473,"journal":{"name":"Enfermedad Inflamatoria Intestinal al Día","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2015-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.eii.2015.08.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84316711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信